Deutsche Bank reissued their buy rating on shares of Shire (LON:SHP) in a research report sent to investors on Thursday morning. They currently have a GBX 5,000 ($67.81) price objective on the biopharmaceutical company’s stock.
Several other analysts also recently weighed in on the company. JPMorgan Chase & Co. reissued an overweight rating on shares of Shire in a report on Wednesday. Citigroup reissued a buy rating and issued a GBX 5,500 ($74.59) target price on shares of Shire in a report on Friday, January 5th. Liberum Capital downgraded Shire to a hold rating and reduced their target price for the company from GBX 4,200 ($56.96) to GBX 4,100 ($55.60) in a report on Wednesday, December 20th. Morgan Stanley reissued an overweight rating and issued a GBX 5,700 ($77.30) target price on shares of Shire in a report on Friday, December 1st. Finally, Societe Generale boosted their target price on Shire from GBX 7,500 ($101.71) to GBX 8,000 ($108.49) and gave the company a buy rating in a report on Wednesday, November 29th. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Shire currently has an average rating of Buy and an average price target of GBX 5,152.94 ($69.88).
Shire (LON SHP) traded down GBX 66.50 ($0.90) during trading on Thursday, hitting GBX 3,581 ($48.56). The stock had a trading volume of 3,220,000 shares, compared to its average volume of 2,250,000. Shire has a fifty-two week low of GBX 3,435.50 ($46.59) and a fifty-two week high of GBX 5,067 ($68.71). The stock has a market cap of $32,500.00 and a P/E ratio of 2,733.59.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.